Artigos de Perspetiva
Theranostics: Are We at a Turning Point for Nuclear Medicine?
Conteúdo principal do artigo
Francisco Norton Brandão
Miguel Barbosa
Detalhes do artigo
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Referências
Sartor, O. PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer. Unpublished data: trial results presented in 2023 European Society for Medical Oncology annual meeting. 2023-09-16. pp. 385(12):1091-1103.
Mileva EG, de Vries T, Guiot Z, Wimana A, Deleu C, Schröder C, et al. Molecular imaging predicts response absence to T-DM1 in advanced HER2-positive breast cancer: final results from a prospective phase II ZEPHIR trial [Online] [accessed 10/11/2023] Available at: https://www.eanm.org/congresses-events/awards-grants/winners/.
Kerrmann K, Schwaiger M, Lewis J, Solomon S, McNeill B, Baumann M, et al. Radioteranostics: a roadmap for future development. Lancet Oncol. 2020;21:e146-56. doi: 10.1016/S1470-2045(19)30821-6.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-103. doi: 10.1056/NEJMoa2107322.
Hofman S, Emmett L, Sandhu S, Iravani A, Joshua A, Goh J, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797-804. doi: 10.1016/S0140-6736(21)00237-3.
European Medicines Agency. Resumo das Características do Medicamento - Pluvicto. [accessed 10/11/2023] Available at: https://www.ema.europa.eu/en/documents/overview/pluvicto-epar-medicine-overview_pt.pdf.
